CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model

Abstract excerpt

BACKGROUND: GPRC6A is implicated in the pathogenesis of prostate cancer, but its role remains uncertain because of a purported tolerant gene variant created by substitution of a K..Y polymorphism in the 3rd intracellular loop (IL) that evolved in the majority of humans and replaces the ancestral RKLP present in 40% of humans of African descent and all other species. METHODS: We determined whether the K..Y...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Transport and Resistance Mechanisms
• Share to Prostate Cancer Treatment and Research
• Share to Receptor Mechanisms and Signaling